Beyond Bapi: Alzheimer’s Pipeline Runs Deep
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
You may also be interested in...
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
The annual BIO conference opened in San Diego with deals being announced at the outset and everyone enthusiastic about partnering.
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.